Nuwellis (NASDAQ:NUWE) is a medical technology company focused on providing therapeutic solutions for patients with fluid overload, a common complication of congestive heart failure, chronic kidney disease and other acute health conditions. The company’s flagship offering, the Aquadex FlexFlow® System, is designed to gently remove excess fluid from patients’ bloodstreams through a minimally invasive extracorporeal therapy. Aquadex allows clinicians to precisely control fluid removal, helping to stabilize hemodynamics and potentially reduce time in intensive care settings compared to traditional diuretic therapies.
In addition to Aquadex, Nuwellis is developing novel applications of its platform technology to address broader unmet needs in fluid management. The company’s research and development efforts include exploring indications such as acute decompensated heart failure and chronic kidney disease, with the goal of expanding the role of controlled ultrafiltration in critical and outpatient care. Nuwellis also maintains a pipeline of investigational devices aimed at improving patient comfort, reducing treatment times and offering alternatives for diuretic-resistant populations.
Founded in 2004 and headquartered in San Carlos, California, Nuwellis initially operated under the name CHF Solutions before rebranding to reflect its broader focus on innovative fluid removal therapies. The company’s products are marketed primarily in the United States, where it works closely with hospitals, dialysis centers and outpatient clinics. Nuwellis continually invests in clinical studies and real-world evidence programs to demonstrate the safety, efficacy and economic benefits of its technology, fostering relationships with leading cardiology and nephrology centers of excellence.
Under the guidance of a management team with extensive experience in medical devices, biopharma and hospital-based care, Nuwellis seeks to address a significant clinical challenge that affects millions of patients worldwide. The company’s board and executive leadership bring together expertise in regulatory affairs, commercial strategy and product development. As Nuwellis advances its therapeutic platform, it remains committed to delivering targeted fluid management solutions that improve outcomes for patients and support healthcare providers in managing complex cardio‐renal conditions.
